Criteria for use of atovaquone oral suspension in adult inpatients and outpatients.
Goodwin
S D
SD
Care Management Division, Glaxo Wellcome Inc., Research Triangle Park, NC 27709, USA.
Fish
D N
DN
D000284:Administration, Oral; D000328:Adult; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D053626:Atovaquone; D002985:Clinical Protocols; D016903:Drug Monitoring; D006801:Humans; D009285:Naphthoquinones / Q000494:pharmacology / Q000627:therapeutic use*; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy*; D016781:Toxoplasmosis, Cerebral / Q000188:drug therapy*
D000935:Antifungal Agents; D000981:Antiprotozoal Agents; D009285:Naphthoquinones; D053626:Atovaquone